GLP-1 medications have become increasingly popular for supporting weight loss and improving metabolic health. More recently, there has been growing interest in oral GLP-1 medications, which offer an alternative to injectable options.

Today, many well-known GLP-1 medications, including Wegovy and Ozempic, are administered by injection. However, Rybelsus is an FDA-approved oral option, and newer pill-based medications such as Foundayo have also recently received FDA approval. 

This shift toward oral GLP-1 medications raises important considerations for patients, particularly those thinking about fertility and family planning. 

What are GLP-1 medications?

GLP-1 (glucagon-like peptide-1) receptor agonists are medications that mimic a natural hormone involved in regulating blood sugar, appetite, and metabolism.

They work through several coordinated mechanisms:

• Stimulating pancreatic beta cells to increase insulin release after meals, helping improve post-meal blood sugar control
• Suppressing pancreatic alpha cells, which reduces glucagon levels (a hormone that raises blood sugar)
• Slowing gastric emptying, allowing food to move more slowly through the digestive system, and increasing feelings of fullness
• Acting on the brain’s appetite centers to reduce hunger and overall calorie intake

Together, these effects support improved metabolic regulation and, in many patients, lead to weight loss.

GLP-1 medications were originally developed for type 2 diabetes but are now widely used for weight management, including Wegovy, Ozempic, Mounjaro, and Zepbound.

Because metabolic health is closely linked to reproductive health, these medications are increasingly part of conversations around fertility, particularly for patients with insulin resistance or PCOS.

How are the GLP-1 pills on the market different? 

Oral GLP-1 medications belong to the same class as injectable options like Wegovy, Ozempic, Mounjaro, and Zepbound — GLP-1 receptor agonists — but differ in their delivery method.

The primary distinction is that oral GLP-1s are taken as a pill rather than administered by injection.

This difference may impact:

• Absorption and bioavailability
• Dosing consistency
• Gastrointestinal tolerance
• Patient preference and adherence

Because oral medications must pass through the digestive system, they may have more variable absorption than injectable formulations, which can influence overall effectiveness and tolerability in some patients. 

In addition, oral GLP-1 medications have unique pharmacokinetic considerations. Injectable GLP-1s are large peptide molecules and are not expected to significantly cross the placenta. Oral formulations, however, rely on an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to facilitate uptake in the stomach.

Unlike the GLP-1 molecule itself, SNAC has been shown to cross the placenta in animal studies and is detectable in breast milk, raising additional considerations for use during pregnancy and lactation. For this reason, while all GLP-1 medications are recommended to be discontinued prior to pregnancy, oral formulations introduce an added layer of consideration due to SNAC exposure.

Because GLP-1 medications also have relatively long half-lives, remaining in the body for several weeks after discontinuation, timing of use in the preconception period should be carefully planned in coordination with a physician. Emerging human data on semaglutide exposure in pregnancy remain limited but are actively being studied.

What are the side effects of GLP-1 pills?

The side effects of oral GLP-1’s are expected to be similar to those of other GLP-1 medications, though individual response can vary.

Common side effects include:

• Nausea
• Vomiting
• Diarrhea or constipation
• Decreased appetite
• Fatigue

These symptoms are often most noticeable when starting the medication or increasing the dose.

Less common but more serious risks may include:

• Pancreatitis
• Gallbladder complications (including gallstones)
• Significant gastrointestinal intolerance

From a reproductive health perspective, these risks are particularly important to consider. Pregnancy itself is associated with an increased risk of gallbladder disease and, more rarely, pancreatitis. When GLP-1 medications are part of the clinical picture, there is growing awareness that these overlapping risk factors may be relevant, particularly if a patient becomes pregnant while recently on treatment.

While research is still evolving, there have been increasing reports linking GLP-1 medications to gallbladder-related issues, including gallstone formation. For this reason, careful timing, monitoring, and preconception planning are important when using these medications.

As always, individual risk should be discussed with a physician, especially for patients who are actively trying to conceive or undergoing fertility treatment.

Is a GLP-1 pill better than an injection?

An oral GLP-1 such as Foundayo may be appealing for patients who prefer not to use injections. However, injectable medications like Wegovy, Ozempic, Mounjaro, and Zepbound currently have more established clinical data. 

Whether a pill or injection is more appropriate depends on:

• Individual medical history
• Treatment goals
• Side effect tolerance
• Provider guidance

Convenience should not be the primary factor in determining the best treatment option.

Even though taking a pill may feel easier than an injection, studies show that GLP-1 pills work just as well as shots for controlling blood sugar. That said, injections are still more effective for weight loss.

Does a GLP-1 pill affect fertility?

GLP-1 medications, including GLP-1 oral pills, do not directly improve fertility.

However, they may indirectly support reproductive health by improving metabolic function — particularly in patients with insulin resistance, PCOS, or obesity-related hormonal imbalance.

Under these conditions, elevated insulin levels can disrupt normal hormonal signaling, potentially preventing regular ovulation (anovulation). Insulin resistance is a key driver of this process, especially in patients with PCOS.

When GLP-1 medications help lower insulin levels and support weight loss, this can, in some cases, restore more regular ovulation. For some individuals who were not previously ovulating, this may lead to the return of spontaneous ovulation.

As a result, patients may become pregnant, sometimes unexpectedly, if they are not using contraception.

This effect varies from person to person and should not be considered a primary treatment for fertility. However, it highlights the close relationship between metabolic health and reproductive function.

Do GLP-1 medications make you more fertile?

In certain conditions, GLP-1 medications may be indirectly associated with improved fertility.

They can:

• Improve insulin sensitivity
• Support weight loss in some patients
• Help regulate ovulatory cycles

In patients with PCOS, obesity, insulin resistance, or diabetes, these changes can be clinically significant. Elevated insulin levels can disrupt normal hormone signaling and contribute to anovulation (lack of ovulation). By improving metabolic function, GLP-1 medications may help restore normal ovulation.

In some cases, this can lead to spontaneous ovulation and the possibility of conception, particularly in patients who were not previously ovulating.

However, GLP-1 medications are not fertility treatments. Their impact on reproductive outcomes is indirect, and research in this area is still evolving.

How long should you be off GLP-1 before trying to conceive?

Due to their long half-life, many providers advise discontinuing GLP-1 medications at least 2 months before attempting conception. 

Timing should always be individualized in consultation with a physician, particularly for patients actively trying to conceive or undergoing fertility treatment.

The development of oral GLP-1 pills represents an evolution in the management of metabolic health.

For patients navigating fertility, these medications may play a supportive role, but they are not a substitute for comprehensive, individualized care.

At Collab Fertility, our approach integrates evidence-based medicine with a broader understanding of metabolic and environmental factors that influence reproductive health. 

For patients planning to freeze eggs or embryos, timing around GLP-1 use is especially important. These medications slow gastric emptying, which can increase the risk of having a “full stomach” at the time of anesthesia. This raises concern for aspiration during sedation, a serious complication that can lead to aspiration pneumonia. 

For this reason, patients are often advised to discontinue GLP-1 medications at least two weeks prior to an egg retrieval procedure, though timing may vary. It is essential to inform your fertility team and anesthesia provider if you are taking a GLP-1 medication, as this directly impacts procedural safety and planning.

Programe una consulta para saber cómo nuestros planes de tratamiento personalizados e integrales pueden apoyar su camino hacia la paternidad.

________________________

Apoyando con orgullo a las comunidades locales
Collab Fertility tiene el honor de servir a familias en East Bay como Danville, Alamo, Orinda, Lafayette, Moraga, Piedmont y Walnut Creek, así como a muchas otras comunidades en el Área de la Bahía y más allá, incluyendo Oakland, San Ramon, Concord, Pleasant Hill, Santa Rosa, Novato, Napa, Sonoma y más.